Recombinant E.coli albA protein

AlbA recombinant protein is derived from the AlbA protein, originally identified in *Staphylococcus aureus*, a Gram-positive bacterium associated with opportunistic infections. AlbA, part of the microbial surface components recognizing adhesive matrix molecules (MSCRAMMs) family, plays a role in bacterial adhesion, biofilm formation, and immune evasion. It binds to host proteins like IgG, contributing to pathogenicity by interfering with immune responses.

The recombinant form of AlbA is produced using genetic engineering techniques, typically through heterologous expression in *E. coli* or other host systems. The gene encoding AlbA is cloned into expression vectors, allowing large-scale production and purification. Recombinant AlbA retains functional domains critical for ligand interactions, enabling studies on its structural properties, adhesion mechanisms, and role in bacterial virulence.

Research on AlbA recombinant protein focuses on understanding *S. aureus* pathogenesis, particularly biofilm-related infections and immune evasion strategies. It serves as a tool for developing therapeutic agents, such as antibodies or inhibitors targeting AlbA-mediated adhesion, and vaccines to block bacterial colonization. Additionally, it aids in diagnostic applications, including antibody detection in infected hosts.

Recent studies also explore AlbA’s potential in nanotechnology due to its self-assembling properties. Its recombinant form offers a controlled model for investigating host-pathogen interactions and designing anti-biofilm therapies. Overall, AlbA recombinant protein is a valuable resource in microbiology, immunology, and biomedical engineering.